Study Name | Region(s) Involved | Study Inclusion & Exclusion Criteria | No. Requested by researchers | No. Identified in EHRs | No. Provided by SHARE to Research Team | No. Recruited | Percentage Identified and Recruited | Percentage Provided and Recruited | Percentage Fulfilled |
---|---|---|---|---|---|---|---|---|---|
A | East | Inclusion: • Age: 18–75 • HFa • Diabetes • On Diuretic Exclusion: • On Insulin therapy | 20 | 68 | 41 | 11 | 16.2 | 26.8 | 55.0 |
B | Southeast | Inclusion: • Female • Age: 18–50 • Complaint of HMBb • Prescription for tranexamic acid or mefenamic acid Exclusion: • Cancer • Severe Coagulation disorder • Diabetes • Hysterectomy | 20 | 402 | 28 | 6 | 1.5 | 21.4 | 30.0 |
C | All | Inclusion: • Age:> 18 • Experienced acute coronary syndrome in the previous six months Exclusion: • Currently in hospital for any reason • Haven’t experienced acute coronary syndrome in the previous two weeks | 177 | NAy | 33 | 16 | /z | 48.5 | 9.0 |
D | East/West | Inclusion: • Age:> 18 • CKDc 3b or 4 Exclusion: • Atrial fibrillation or flutter • On warfarin • Unable to give consent • Taking Vitamin K • Known contraindication to Vitamin K • Intolerance to soya product • Pregnant or capable of child-bearing • Currently in another trial or within 30 days of completing another trial | 165 | 237 | 35 | 7 | 3.0 | 20.0 | 4.2 |
E | Southeast | Inclusion: • Age: 40–90 • Healthy Exclusion: • Diseases of eye and adnexa • Inflammatory diseases of the central nervous system • Systemic atrophies primarily affecting the central nervous system • Extrapyramidal and movement disorders • Other degenerative diseases of the nervous system • Demyelinating diseases of the central nervous system • Vascular syndromes of brain in cerebrovascular diseases • Cerebral palsy and other paralytic syndromes • Stroke, not specified as haemorrhage or infarction | 150 | 809 | 150 | 79 | 9.8 | 52.7 | 52.7 |
F | East | Inclusion: • LILRB5 rs12975366 genotype of either T/T or C/C • Males aged 61–69 years or Females aged 40–69 • Not on statin Exclusion: • More than 3 prescriptions in last 12 months | 40 | 136 | 33 | 17 | 12.5 | 51.5 | 42.5 |
G | East | Inclusion: • Age:18–80 • White European • Able to complete the symptom severity score and Bristol stool chart independently • eGFRd > 60 Exclusion: • Diabetes • Involvement in CTIMPe within 30 days • Pregnancy or planning to conceive • Metformin history • Gastrointestinal pathology • Daily treatment with PPIf, anti-spasmodic, or anti-motility drugs or OCT1g inhibiting drugs | 40 | 254 | 8 | 8 | 3.1 | 100.0 | 20.0 |
H | Southeast | Exclusion: • Age:18–64 (inclusion) • have a primary DSM-5h diagnosis of MDDi • Not responding to at least 1 antidepressant currently taken • be able to complete study questionnaires Exclusion: • Axis I psychiatric condition • Onset of depression after 55 years of age • Organic brain disease or demented • Mental retardation • Malignancy within the 5 years • HIV • Infection of hepatitis B virus • Congestive heart failure • Demyelinating diseases • Gastrointestinal perforation | 5 | 88 | 15 | 5 | 5.7 | 33.3 | 100.0 |
I | Southeast | Exclusion: • Age: ≥18 years old • men or post-menopausal women (women with no periods for at least 12 months or having a surgical menopause) • Hypertension Exclusion: • Ischaemic heart disease • Cardiac failure • Cerebrovascular disease • Liver impairment disease • CKD stage 3–5 • Overdose or suicidal ideation • Weight less than 55 kg • Chronic pain requiring treatment • with a known allergy to paracetamol • concomitant use of NSAIDs, oral anticoagulants or corticosteroids | 20 | 521 | 36 | 7 | 1.3 | 19.4 | 35.0 |
J | North | Inclusion: • Males aged 18 or over • Females, postmenopausal (least 2 years without menstruation) • BMIj:19–35 • Healthy, free of long-term medication Exclusion: • Age: < 18 • Females, pre- or peri-menopausal (less than 2 years since last period) • Smoking • Drug abuse • Acohol > 20 units/week • Extreme diets or supplementation • Physical or mental health problems • Long-term medication | 36 | 372 | 11 | 4 | 1.1 | 36.4 | 11.1 |
K | East | Inclusion: • Age: 18–75 • NAFLDk or NASHl or Hepatic fibrosis Exclusion: • Any other liver condition • Type 1 Diabetes • BMI < 25 or > 45 • Previous Bariatric surgery • History of proliferative retinopathy • History of pancreatitis • Any malignancy (except basal and squamous cell skin cancers) within the past 5 years • eGFR < 30 ml/min/1.73 m2 • On Vitamin E or pioglitazone within 90 days • On corticosteroids, methotrexate or tamoxifen or valproic acid or amiodarone, tetracycline within 28 days • HbA1cm > 9% • On GLP-1n RAso or SGLT-2p inhibitors within 90 days | 3 | 87 | 9 | 1 | 1.1 | 11.1 | 33.3 |
L | East | Inclusion: • Age: 18–80 • Type 2 diabetes • HF • LVSDq • On Furosemide or bumetanide or torasemide Exclusion: • Age: < 18 or > 80 • Type 1 Diabetes (E10) • Chronic Liver Disease • Receiving dialysis • Malignancy (receiving active treatment) • Past or current treatment with SGLT2 inhibitor • On thiazide diuretics | 26 | 41 | 13 | 2 | 4.9 | 15.4 | 7.7 |
M | Southeast | Inclusion: • 65 years old or older • Residents of Edinburgh or surrounding areas (including Lothians) Exclusion: • Have a history of dementia • Stroke • Other neurological disorders • Traumatic brain injury • Major psychiatric disorders | 300 | 1000 | 132 | 69 | 6.9 | 52.3 | 23.0 |
N | East | Inclusion: • Age ≧40 and ≦80 • Age of diabetes diagnosis ≧35 • T2DMr/NIDDMs • Metformin monotherapy • HbA1c ≦8% (64 mmol/mmol) • eGFR ≧50 ml/min-1 • ALTt ≦2.5*ULNu Exclusion: • Type 1 Diabetes Mellitus • Anaemia (Haemoglobin < 12.0 g/dL for women, < 13.0 g/dL for men) • Pregnancy, lactation or a female planning to conceive within the study period • Established pancreatic disease • Participating in clinical phase of another interventional trial/study or have done so within the last 30 days | 20 | 169 | 22 | 7 | 4.1 | 31.8 | 35.0 |
O | Southeast | Inclusion: • Males and females aged 18–40 years (inclusive at selection) • Body mass index between 18.5-25 kg/m2 (lean group) or 30–55 kg/m2 (obese group) • No acute or chronic medical conditions Exclusion: • Major psychiatric illness • Recurrent depression/ cyclothymic disorder • Diabetes • Anti-diabetic drugs • Anti-depressants and mood altering drugs • Beta-blockers • Anticoagulants and antiplatelets • Glucocorticoids | 18 | 233 | 32 | 7 | 3.0 | 21.9 | 38.9 |
P | West | Inclusion: • Male or female, between and including 40–85 years of age • A confirmed physician diagnosis of COPDv • Current or ex-smoker with ≥10 pack years of smoking history. • Post bronchodilator FEV1w/FVCx ratio < 0.7 • Post bronchodilator FEV1 ≥ 40% of the predicted value. • To have had 1 or more COPD exacerbations in the last 12 months requiring intervention with oral corticosteroids and/or antibiotics such as Penicillins, Macrolides, Tetracyclines, Quinolones, Corticosteroids • Should be prescribed and taking regularly one or more long acting bronchodilator (e.g. long acting? 2 agonist [LABA], long acting muscarinic antagonist [LAMA]) with or without an inhaled corticosteroid maintenance therapy for their COPD such as Broncodilators, Corticosteroids (for more than 6 months) Exclusion: • Active interstitial lung disease • Past history of lung cancer • Significant bronchiectasis • Cystic fibrosis • Alpha-1 antitrypsin deficiency • History of significant chronic asthma • Patients who are currently receiving anti-epileptic therapy and/or have uncontrolled epilepsy • Patients with unstable ischaemic heart disease (including, but not limited to, unstable angina • Myocardial infarction) within 6 months • Stroke within the preceding 6 months | 5 | 496 | 18 | 2 | 0.4 | 11.1 | 40.0 |
Median (Interquartile) | 20 (19–40) | 235 (100–395) | 28 (14–34) | 7 (5–10) | 3.1 (1.4–5.5) | 26.8 (19.7–42.5) | 33.3 (15.6–39.5) |